Tenapanor May Improve Uncontrolled Hyperphosphatemia
By blocking paracellular phosphate transport, tenapanor added to phosphate binders may improve the hyperphosphatemia management in patients on maintenance dialysis, a study found.
By blocking paracellular phosphate transport, tenapanor added to phosphate binders may improve the hyperphosphatemia management in patients on maintenance dialysis, a study found.
Adding aliskiren to losartan in patients with nondiabetic chronic kidney disease does not result in a greater renal protection and increases their risk of hyperkalemia, a study found.
Patients with CKD who discontinued ACE inhibitors or angiotensin receptor blockers after a hyperkalemia episode had a 2.6-fold increased risk of all-cause mortality compared with patients who continued taking the drugs.
Newly released safety data also show that roxadustat is associated with reduced cardiovascular risks compared with epoetin alfa.
In a study, approximately one-fifth of CKD patients with metabolic acidosis received a diagnostic code for it.
Hyperkalemia in patients with chronic kidney disease (CKD) stage 3 or 4 more than doubles their risk of progressing to CKD stage 5, a study found.
Gout that develops in kidney transplant recipients increases their risk of worse outcomes, according to 2 new studies.
In a study, two-thirds of hemodialysis patients met criteria for frailty, which impairs independence, cognition, mood, and quality of life.
Kidney disease patients who took magnesium-containing antacids were 15% more likely to experience hip fracture than nonusers of antacids.
In turn, individuals with post-dialysis hypertension have significantly greater risks for all-cause mortality.